Formulation and Evaluation of Niosomal Vesicles containing Ondansetron HCL for Trans-mucosal nasal drug delivery.

Formulation and Evaluation of Niosomal Vesicles containing Ondansetron HCL for Trans-mucosal nasal drug delivery. Drug Dev Ind Pharm. 2020 Apr 06;:1-43 Authors: Teaima MH, El Mohamady AM, El-Nabarawi MA, Mohamed AI Abstract Ondansetron HCl is a (5-HT3) serotonin receptor antagonist, used as anti-emetic drug in combination with anticancer agents. Conventional dosage forms have poor bioavailability and patient compliance. These problems can be reduced by the use of nasal niosomal thermo reversible in situ gelling system; Niosomes were formulated using various surfactants (Span 60, Span 80, Tween 20 and Tween 80) in different ratios using thin film hydration technique. Niosomes were evaluated for particle size, zeta potential, Transmission Electron Microscopy (TEM) imaging, drug entrapment efficiency and in-vitro drug release. Niosomes prepared using span 60 and cholesterol in the ratio 1:1 (F5) showed higher entrapment efficiency (76.13 ± 1.2%) and in-vitro drug release (91.76%) after 12 hrs. was optimized. The optimized niosomes were developed into thermo reversible in situ gel, composed of Poloxamer 407& sodium carboxymethyl cellulose, prepared by cold method. Compatibility study (FTIR, DSC) was made for drug and excipients that showed no significant interaction. The gel formulation G5 showed the most suitable gelation Temp. (31 °C), Viscosity (1250 mpois), bio adhesion force (5860 ± 28 dyne/cm2), and in-vitro dr...
Source: Drug Development and Industrial Pharmacy - Category: Drugs & Pharmacology Tags: Drug Dev Ind Pharm Source Type: research